Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP71499.RARLO0bUZJ8xsisFuhsQi46FqK1r_GdMVNXYJlszf40T4130_assertion description "[Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP71499.RARLO0bUZJ8xsisFuhsQi46FqK1r_GdMVNXYJlszf40T4130_provenance.
• NP20662.RAt_Q4ZdVthML4DbXRILtBznvCj09kDUYmmqy0I32JKSs130_assertion description "[Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP20662.RAt_Q4ZdVthML4DbXRILtBznvCj09kDUYmmqy0I32JKSs130_provenance.
• NP20674.RAfYmxKkBWUbHhYmvBZnoprMjk5SWgk2Ac6Hg3iKQExbw130_assertion description "[Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP20674.RAfYmxKkBWUbHhYmvBZnoprMjk5SWgk2Ac6Hg3iKQExbw130_provenance.
• NP20654.RA0K6Nh5wWt3m7yOY-xKjyJt1_baC6DO4R4mf6bsRnUl4130_assertion description "[Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP20654.RA0K6Nh5wWt3m7yOY-xKjyJt1_baC6DO4R4mf6bsRnUl4130_provenance.
• NP71510.RAKxbHg3yDNdjlCMAnkrZDAOytkGnmvUd1A9hF_LtcWH0130_assertion description "[Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP71510.RAKxbHg3yDNdjlCMAnkrZDAOytkGnmvUd1A9hF_LtcWH0130_provenance.
• NP19966.RAZKOsZMaJz3qXrA05SdOngpW_HXesw2EH2nY4Bd2UkcY130_assertion description "[Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP19966.RAZKOsZMaJz3qXrA05SdOngpW_HXesw2EH2nY4Bd2UkcY130_provenance.
• NP19951.RA1HRuw2O99TD7Lh8tWVQVUy-h-IwltAgKvc8HPQf50tg130_assertion description "[Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP19951.RA1HRuw2O99TD7Lh8tWVQVUy-h-IwltAgKvc8HPQf50tg130_provenance.
• assertion description "[Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP726188.RAPOUFnt1ZltqCDGWdGf8Viv9a22-XhFHsEED8l03q3bI130_assertion description "[Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP726188.RAPOUFnt1ZltqCDGWdGf8Viv9a22-XhFHsEED8l03q3bI130_provenance.
• NP726189.RA9MVzfj5_dkeeQCI1IMQ0Puh9E_-H1AjRgbGysLyuRCA130_assertion description "[Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP726189.RA9MVzfj5_dkeeQCI1IMQ0Puh9E_-H1AjRgbGysLyuRCA130_provenance.